Deregulated expression of the Per1 and Per2 in human gliomas

Canadian Journal of Neurological Sciences

Volumn 37, Issue 3, 2010, Pages 365-370

  Xia, He Chun ^a   Niu, Zhan Feng ^a   Ma, Hui ^a   Cao, Shuan Zhu ^a   Hao, Shao Cai ^a   Liu, Zhong Tao ^a   Wang, Fan ^a  

^a AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PER1 PROTEIN; PER2 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CHILD; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD;

EID: 77950673875     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710001026X     Document Type: Article

References (31)

1. Gromeier M, Wimmer E. Viruses for the treatment of malignant glioma. Curr Opin Mol Ther. 2001; 3 (5): 503-508
2. Rainov N, Ren H. Gene therapy for human malignant brain tumors. Cancer J. 2003; 9 (3): 180-188
3. Aschhoff B. Retrospective study of Ukraine treatment in 203 patients with advanced-stage tumors. Drugs Exp Clin Res. 2000; 26 (5-6): 249-252
4. Sun JY, Yang H, Miao S, Li JP, Wang SW, Zhu MZ, et al. Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. J Phymed. 2009; 16 (11): 1070-1074
5. Stummer W. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7 (5): 392-401.
6. Fujioka A, Takashima N, Shigeyoshi Y. Circadian rhythm generation in a glioma cell line. Biochem Biophys Res Commun. 2006; 346 (1): 169-174
7. Perou CM, Serlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000; 406 (6797): 747-752
8. Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002; 44 (2): 121-141
9. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002; 21 (35): 5462-5482
10. Balsalobre A. Clock genes in mammalian peripheral tissues. Cell Tissue Res. 2002; 309 (1): 193-199
11. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol. 2001; 63: 647-676
12. Metz RP, Qu X, Laffin B, Earnest D, Perter WW. Circadian clock and cell cycle gene expression in mouse mammary epithelial cells and in the developing mouse mammary gland. Dev Dyn. 2006; 235 (1): 263-271
13. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the Per1, Per2, Per3 genes in breast cancers. Carcinogenesis. 2005; 26 (7): 1241-1246
14. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002; 94 (9): 690-697
15. Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF, et al. Abnormal expression of Period 1 (Per1) in endometrial carcinoma. J Pathol. 2005; 206 (1): 111-120
16. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, et al. Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther. 2007; 14 (9): 815-818
17. Tcrpe HJ, Storkel S, Zimmer U, Anquez V, Fischer C, Pantel K, et al. Expression of CD44 isoforms in renal cell tumors. Am J Pathol. 1996; 148 (2): 453-463
18. Bjarnason GA, Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res. 2000; 4: 193-206.
19. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003; 302 (5643): 255-259
20. Smaaland R, Lote K, Sothern RB, Laerum OD. DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Cancer Res. 1993; 53: 3129-3138
21. Panda S, Antoch MP, Miller BH, Su AI, Schock AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002; 109 (3): 307-320
22. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417 (6884): 78-83.
23. Duffield GE, Best JD, Meurers BH, Bittner A, Loros JJ, Dunlap JC. Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells. Curr Biol. 2002; 12 (7): 551-557
24. Kornmann B, Preitner N, Rifat D, Fleuury-Olela F, Schibler U. Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs. Nucl Acids Res. 2001; 29 (11): E51.
25. Le Minh N, Damiola F, Tronche F, Schutz G, Schibler U. Glucocorticoid hormones inhibit food-induced phaseshifting of peripheral circadian oscillators. EMBO J. 2001; 20 (24): 7128-7136
26. Hrushesky WJM, Bjarnason GA. Circadian cancer therapy. J Clin Oncol. 1993; 11 (7): 1403-1417
27. Levi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001; 2 (5): 307-315
28. Focan C. Circadian rhythms and cancer chronotherapy. Pharmacol Ther. 1995; 67 (1): 1-52.
29. Mormont MC, Levi F. Cancer chronotherapy: principle, applications and perspectives. Cancer. 2003; 97 (1): 155-169
30. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111 (1): 41-50.
31. Lee CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control. 2006; 17 (4): 525-530